Product
ALZN002
1 clinical trial
1 indication
Indication
Alzheimer's diseaseClinical trial
Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's DementiaStatus: Active (not recruiting), Estimated PCD: 2028-03-03